State of Tennessee Department of Treasury Trims Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

State of Tennessee Department of Treasury lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 54.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,730 shares of the specialty pharmaceutical company's stock after selling 4,414 shares during the quarter. State of Tennessee Department of Treasury's holdings in ANI Pharmaceuticals were worth $206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ANIP. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the period. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $166,000. China Universal Asset Management Co. Ltd. grew its position in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares during the last quarter. Finally, Integrated Quantitative Investments LLC purchased a new position in ANI Pharmaceuticals in the 4th quarter valued at $271,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ANIP. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $5.25 during trading on Friday, hitting $66.28. 756,687 shares of the company were exchanged, compared to its average volume of 291,084. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -120.51 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00. The firm's fifty day moving average price is $66.86 and its 200 day moving average price is $60.70. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period in the previous year, the firm earned $0.82 EPS. The business's revenue for the quarter was up 43.4% compared to the same quarter last year. On average, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. The trade was a 1.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $197,792 in the last three months. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.